Piper Sandler previously had a neutral for Aligos Therapeutics Inc. The last downgrade for Aligos Therapeutics Inc happened on May 5, 2022 when SVB Leerink changed their price target from $7 to $3 ...

The scale of infections has led to predictions of very high sales for the first RSV vaccines to reach the market, with analysts at SVB Leerink predicting the market could reach upwards of $10 ...

On 3 rd June, financial analyst Geoffrey Porges of SVB Leerink predicted that remdesivir would deliver revenues approaching $2 billion in 2020, rising to $7.7 billion by 2022. These figures are ...

J.P. Morgan analyst Anne E. Samuel reiterated the Neutral rating on Premier, Inc. (NASDAQ:PINC) on Tuesday, with a price ...

Nkarta, Inc. (NASDAQ:NKTX – Free Report) – Research analysts at Leerink Partnrs raised their Q1 2025 earnings estimates for shares of Nkarta in a research report issued on Wednesday ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $2.11 per share for the quarter, down from their previous estimate of $2.21.

In a report released on March 24, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The company’s shares closed yesterday at $18.19.

Leerink analyst Michael Cherny initiated coverage of Medpace (MEDP) with a Market Perform rating and $330 price target The firm notes Medpace is a leading contract research organization that ...

March 7, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Leerink ...

I think we'll get started. Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno ...